Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hill, Rebecca M. [VerfasserIn]   i
 Plasschaert, Sabine L. A. [VerfasserIn]   i
 Timmermann, Beate [VerfasserIn]   i
 Dufour, Christelle [VerfasserIn]   i
 Aquilina, Kristian [VerfasserIn]   i
 Avula, Shivaram [VerfasserIn]   i
 Donovan, Laura [VerfasserIn]   i
 Lequin, Maarten [VerfasserIn]   i
 Pietsch, Torsten [VerfasserIn]   i
 Thomale, Ulrich [VerfasserIn]   i
 Tippelt, Stephan [VerfasserIn]   i
 Wesseling, Pieter [VerfasserIn]   i
 Rutkowski, Stefan [VerfasserIn]   i
 Clifford, Steven C. [VerfasserIn]   i
 Pfister, Stefan [VerfasserIn]   i
 Bailey, Simon [VerfasserIn]   i
 Fleischhack, Gudrun [VerfasserIn]   i
Titel:Relapsed medulloblastoma in pre-irradiated patients
Titelzusatz:current practice for diagnostics and treatment
Verf.angabe:Rebecca M. Hill, Sabine L.A. Plasschaert, Beate Timmermann, Christelle Dufour, Kristian Aquilina, Shivaram Avula, Laura Donovan, Maarten Lequin, Torsten Pietsch, Ulrich Thomale, Stephan Tippelt, Pieter Wesseling, Stefan Rutkowski, Steven C. Clifford, Stefan M. Pfister, Simon Bailey and Gudrun Fleischhack
Jahr:2022
Umfang:34 S.
Fussnoten:Online verfügbar: 28 December 2021 ; Gesehen am 28.09.2022
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2022
Band/Heft Quelle:14(2022), 1, Artikel-ID 126, Seite 1-34
ISSN Quelle:2072-6694
Abstract:Relapsed medulloblastoma (rMB) accounts for a considerable, and disproportionate amount of childhood cancer deaths. Recent advances have gone someway to characterising disease biology at relapse including second malignancies that often cannot be distinguished from relapse on imaging alone. Furthermore, there are now multiple international early-phase trials exploring drug-target matches across a range of high-risk/relapsed paediatric tumours. Despite these advances, treatment at relapse in pre-irradiated patients is typically non-curative and focuses on providing life-prolonging and symptom-modifying care that is tailored to the needs and wishes of the individual and their family. Here, we describe the current understanding of prognostic factors at disease relapse such as principal molecular group, adverse molecular biology, and timing of relapse. We provide an overview of the clinical diagnostic process including signs and symptoms, staging investigations, and molecular pathology, followed by a summary of treatment modalities and considerations. Finally, we summarise future directions to progress understanding of treatment resistance and the biological mechanisms underpinning early therapy-refractory and relapsed disease. These initiatives include development of comprehensive and collaborative molecular profiling approaches at relapse, liquid biopsies such as cerebrospinal fluid (CSF) as a biomarker of minimal residual disease (MRD), modelling strategies, and the use of primary tumour material for real-time drug screening approaches.
DOI:doi:10.3390/cancers14010126
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.3390/cancers14010126
 Volltext: https://www.mdpi.com/2072-6694/14/1/126
 DOI: https://doi.org/10.3390/cancers14010126
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:medulloblastoma
 relapse
K10plus-PPN:1817689568
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68968958   QR-Code
zum Seitenanfang